*SomaLogic Operating Co. Inc.
SomaLogic boasts industry-leading reliability metrics that include sensitivity, specificity, and reproducibility. Learn More
The University of Colorado Connection
Professor Larry Gold (CU Boulder MCDB) founded SomaLogic, which pioneered the development of proteomics diagnostics and assays based on Gold’s SELEX technology. After going public in 2021, SomaLogic announced a merger with Standard BioTools in 2023.
Funding Status and Investment Opportunities
- Industry: Biotech, Genomics, Health and Wellness, Therapeutics, Diagnostics
- Funding Stage: Exit
- Contact for Investment Inquiries: Standard Bio Tools Inc. (LAB)
In the News
- Long COVID linked to ongoing immune activation, cell damage in proteomics study (2023)
- Standard BioTools completes merger with SomaLogic, a CU Boulder spinout (2023)
- SomaLogic to merge with Standard BioTools in all-stock deal (2023)
- SomaLogic partners with Dante Genomics to enhance clinical and research adoption of proteomics in Europe (2023)
- SomaLogic acquires DNA nanotechnology leader Palamedrix (2022)
- SomaLogic to aid in cancer research (2022)
- SomaLogic predicts $110M in 2022 revenue (2022)
- SomaLogic to go public via SPAC in deal that values it as a unicorn (2021)
This page was last updated Sept. 3, 2024. Please contact us for corrections or updates